Thera-SAbDab

LETOLIZUMAB

>   Structural Summary
TherapeuticLetolizumab
TargetCD40LG
Heavy ChainEVQLLESGGGLVQPGGSLRLSCAASGFTFNWELMGWARQAPGKGLEWVSGIEGPGDVTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCVKVGKDAKSDYRGQGTLVTVSS
Light Chainna
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatSingle Domain Variable Fragment;H
IsotypeG1
Highest Clinical Trial (June '19)Phase-I/II
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2016
INN Year Recommended2017
Companies InvolvedBristol-Myers Squibb, H. Lee Moffitt Cancer Center and Research Institute
Conditions Approvedna
Conditions ActiveGraft-versus-host disease, Idiopathic thrombocytopenic purpura
Conditions Discontinuedna
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]